loading...| Preferred Name |
pentoxifylline |
|
| Synonyms |
Pentoxyphylline |
|
| Definitions |
A methylxanthine derivative with hemorrheologic and immunomodulating properties. Pentoxifylline inhibits phosphodiesterase, resulting in increased levels of cyclic adenosine monophosphate (cAMP) in erythrocytes, endothelium, and the surrounding tissues. This leads to vasodilation, improves erythrocyte flexibility, and enhances blood flow. In addition, the increased level of cAMP in platelets inhibits platelet aggregation, which may contribute to a reduction in blood viscosity. This agent also inhibits production of tumor necrosis factor-alpha and interferon-gamma, while it induces Th2-like (T-helper 2) cytokine production, thereby inhibiting Th1-mediated (T-helper 1) inflammatory and autoimmune responses. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C733" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C733" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000041432 |
|
| altLabel |
Pentoxyphylline 3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione oxpentifylline PTX Trental |
|
| CAS Registry |
6493-05-6 |
|
| Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000041904 http://purl.bioontology.org/ontology/PDQ/CDR0000041506 http://purl.bioontology.org/ontology/PDQ/CDR0000042206 http://purl.bioontology.org/ontology/PDQ/CDR0000042812 http://purl.bioontology.org/ontology/PDQ/CDR0000041436 http://purl.bioontology.org/ontology/PDQ/CDR0000041923 http://purl.bioontology.org/ontology/PDQ/CDR0000041921 http://purl.bioontology.org/ontology/PDQ/CDR0000038372 http://purl.bioontology.org/ontology/PDQ/CDR0000042054 http://purl.bioontology.org/ontology/PDQ/CDR0000041870 |
|
| cui |
C0699487 C0030899 |
|
| definition |
A methylxanthine derivative with hemorrheologic and immunomodulating properties. Pentoxifylline inhibits phosphodiesterase, resulting in increased levels of cyclic adenosine monophosphate (cAMP) in erythrocytes, endothelium, and the surrounding tissues. This leads to vasodilation, improves erythrocyte flexibility, and enhances blood flow. In addition, the increased level of cAMP in platelets inhibits platelet aggregation, which may contribute to a reduction in blood viscosity. This agent also inhibits production of tumor necrosis factor-alpha and interferon-gamma, while it induces Th2-like (T-helper 2) cytokine production, thereby inhibiting Th1-mediated (T-helper 1) inflammatory and autoimmune responses. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C733" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C733" NCI Thesaurus) |
|
| Legacy PDQ ID |
4502 |
|
| LT |
TRD |
|
| NCI ID |
C733 |
|
| notation |
CDR0000041432 |
|
| NSC Code |
637086 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
pentoxifylline |
|
| tui |
T109 T121 |